drugset

drugset / Trial / NCT00199849

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

NCT00199849 ↗

Phase 1 Completed 18 enrolled Ludwig Institute for Cancer Research M.D. Anderson Cancer Center · collab Memorial Sloan Kettering Cancer Center · collab New York Presbyterian Hospital · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.

Timeline

Start: 2004-09-27
Primary completion: 2006-09-11
Completion: 2007-09

Publications

Background Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NY-ESO-1 Plasmid DNA Cancer Vaccine	Vaccine	4 ug	Other
Subject	NY-ESO-1 Plasmid DNA Cancer Vaccine	Vaccine	8 ug	Other

Indications